Cytek Biosciences - CTKB Stock Price Target and Predictions

  • Consensus Rating: Moderate Buy
  • Consensus Price Target: $9.00
  • Forecasted Upside: 45.87%
  • Number of Analysts: 5
  • Breakdown:
  • 0 Sell Ratings
  • 2 Hold Ratings
  • 3 Buy Ratings
  • 0 Strong Buy Ratings
$6.17
▼ -0.13 (-2.06%)

This chart shows the closing price for CTKB by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Cytek Biosciences Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for CTKB and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for CTKB

Analyst Price Target is $9.00
▲ +45.87% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for Cytek Biosciences in the last 3 months. The average price target is $9.00, with a high forecast of $10.00 and a low forecast of $7.00. The average price target represents a 45.87% upside from the last price of $6.17.

This chart shows the closing price for CTKB for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Moderate Buy

The current consensus among 5 polled investment analysts is to moderate buy stock in Cytek Biosciences. This Moderate Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 3 buy ratings
  • 2 hold ratings
  • 0 sell ratings
10/21/2022
  • 0 strong buy ratings
  • 3 buy ratings
  • 2 hold ratings
  • 0 sell ratings
1/19/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 2 hold ratings
  • 0 sell ratings
4/19/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 2 hold ratings
  • 0 sell ratings
7/18/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 2 hold ratings
  • 0 sell ratings
10/16/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 2 hold ratings
  • 0 sell ratings
1/14/2024
  • 0 strong buy ratings
  • 3 buy ratings
  • 2 hold ratings
  • 0 sell ratings
3/14/2024
  • 0 strong buy ratings
  • 3 buy ratings
  • 2 hold ratings
  • 0 sell ratings
4/13/2024

Latest Recommendations

  • 0 strong buy ratings
  • 3 buy ratings
  • 2 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/6/2024Piper SandlerLower TargetOverweight ➝ Overweight$11.00 ➝ $10.00Low
2/29/2024The Goldman Sachs GroupBoost TargetBuy ➝ Buy$9.00 ➝ $10.00Low
12/14/2023StephensInitiated CoverageOverweight$9.00Low
11/9/2023Morgan StanleyLower TargetEqual Weight ➝ Equal Weight$8.00 ➝ $7.00Low
10/24/2023Morgan StanleyLower TargetEqual Weight ➝ Equal Weight$13.00 ➝ $8.00Low
10/16/2023Piper SandlerLower TargetOverweight ➝ Overweight$15.00 ➝ $10.00Low
7/18/2023Raymond JamesInitiated CoverageMarket PerformLow
3/7/2023Piper SandlerLower TargetOverweight$18.00 ➝ $15.00Low
3/2/2023Morgan StanleyLower TargetEqual Weight$15.00 ➝ $14.00Low
3/2/2023The Goldman Sachs GroupLower TargetBuy$16.00 ➝ $14.00Low
11/14/2022Piper SandlerBoost Target$16.00 ➝ $18.00Low
8/17/2022Piper SandlerBoost TargetOverweight$12.00 ➝ $16.00Low
8/12/2022Morgan StanleyBoost TargetEqual Weight$11.00 ➝ $15.00Low
8/11/2022The Goldman Sachs GroupBoost TargetBuy$15.00 ➝ $17.00Low
7/14/2022The Goldman Sachs GroupBoost TargetBuy$12.00 ➝ $15.00Low
5/15/2022Piper SandlerLower TargetNA$17.00 ➝ $12.00High
4/13/2022The Goldman Sachs GroupLower TargetBuy$28.00 ➝ $14.00High
3/1/2022Piper SandlerLower Target$20.00 ➝ $17.00High
2/15/2022Morgan StanleyLower TargetEqual Weight$27.00 ➝ $18.00High
8/17/2021CowenInitiated CoverageOutperformHigh
8/17/2021Morgan StanleyInitiated CoverageEqual Weight$26.00High
8/17/2021The Goldman Sachs GroupInitiated CoverageBuy$28.00High
8/17/2021Piper SandlerInitiated CoverageOverweight$28.00High
(Data available from 4/14/2019 forward)

News Sentiment Rating

1.13 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 7 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/17/2023
  • 8 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/17/2023
  • 3 very positive mentions
  • 5 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
11/16/2023
  • 2 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/16/2023
  • 3 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
1/15/2024
  • 4 very positive mentions
  • 0 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
2/14/2024
  • 4 very positive mentions
  • 9 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
3/15/2024
  • 10 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/14/2024

Current Sentiment

  • 10 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Cytek Biosciences logo
Cytek Biosciences, Inc., a cell analysis solutions company, provides cell analysis tools that facilitates scientific advances in biomedical research and clinical applications. It offers aurora and northern lights systems, which are spectrum flow cytometers that delivers cell analysis by utilizing the fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells; and aurora cell sorter system that leverages full spectrum profiling technology to further broaden potential applications across cell analysis; aurora CS systems; amnis imagestream imaging flow cytometers; guava muse cell analyzers; guava easycyte flow cytometers; and orion reagent cocktail preparation systems. The company also provides reagents and kits, including cFluor reagents that are fluorochrome conjugated antibodies used to identify cells of interest for analysis on its instruments, as well as 25-color immunoprofiling assay that provides turnkey solutions for identifying major human immune subpopulations for TBNK cells, monocytes, dendritic cells, and basophils. In addition, it offers automated micro-sampling system and automated sample loader system, an automated loaders to integrate seamlessly into the aurora and northern lights systems; SpectroFlo software that provides intuitive workflow from quality control to data analysis for aurora and northern lights systems; and customer support tools. The company serves pharmaceutical and biopharma companies, academic research centers, and clinical research organizations. It distributes its products through direct sales force and support organizations in North America, Europe, China, and the Asia-Pacific regions; and through distributors or sales agents in European, Latin American, and the Middle Eastern countries. The company was formerly known as Cytoville, Inc. and changed its name to Cytek Biosciences, Inc. in August 2015. Cytek Biosciences, Inc. was founded in 1992 and is headquartered in Fremont, California.
Read More

Today's Range

Now: $6.17
Low: $6.12
High: $6.25

50 Day Range

MA: $7.43
Low: $6.17
High: $9.15

52 Week Range

Now: $6.17
Low: $3.80
High: $12.31

Volume

465,540 shs

Average Volume

690,203 shs

Market Capitalization

$807.16 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.37

Frequently Asked Questions

What sell-side analysts currently cover shares of Cytek Biosciences?

The following Wall Street analysts have issued stock ratings on Cytek Biosciences in the last year: Morgan Stanley, Piper Sandler, Raymond James, Stephens, and The Goldman Sachs Group, Inc..
View the latest analyst ratings for CTKB.

What is the current price target for Cytek Biosciences?

4 Wall Street analysts have set twelve-month price targets for Cytek Biosciences in the last year. Their average twelve-month price target is $9.00, suggesting a possible upside of 45.9%. The Goldman Sachs Group, Inc. has the highest price target set, predicting CTKB will reach $10.00 in the next twelve months. Morgan Stanley has the lowest price target set, forecasting a price of $7.00 for Cytek Biosciences in the next year.
View the latest price targets for CTKB.

What is the current consensus analyst rating for Cytek Biosciences?

Cytek Biosciences currently has 2 hold ratings and 3 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for CTKB.

What other companies compete with Cytek Biosciences?

How do I contact Cytek Biosciences' investor relations team?

The company's listed phone number is 877-922-9835 and its investor relations email address is [email protected]. The official website for Cytek Biosciences is www.cytekdev.com. Learn More about contacing Cytek Biosciences investor relations.